Reco Bio announced pre-clinical research data: ReCOV vaccine has good cross-immunity activity against a variety of mutant strains

Taizhou, Jiangsu, November 9, 2021/PRNewswire/ - Jiangsu Ruike Biotechnology Co.

Dr.

This study used a variety of methods and showed that after two doses of ReCOV vaccine, high levels of neutralizing antibodies are produced.

In the CAG-hACE2 transgenic mouse model, ReCOV can protect mice against the lethal infection of SARS-CoV-2 virus.

More importantly, ReCOV can induce the body to produce powerful neutralizing antibodies and protect rhesus monkeys from the new coronavirus infection

These results support the further clinical development of ReCOV, which is currently being evaluated in a phase I clinical trial in New Zealand (NCT04818801)

About the recombinant two-component new coronary pneumonia vaccine ReCOV

In May 2020, Reco Bio, together with the Jiangsu Provincial Center for Disease Control and Prevention, and the Taizhou Medical Park Administrative Committee, jointly developed a recombinant two-component new coronary pneumonia vaccine (CHO cell) (hereinafter referred to as ReCOV vaccine)

About Ruike Bio

Ruike Biotechnology is an innovative vaccine company founded in 2012.

The information published in this press release may contain certain forward-looking statements

These forward-looking statements are based on the current views, assumptions, expectations, estimates, forecasts and understandings of the company’s management on future affairs at the time the statement is made